Skip to content Skip to footer
Subscribe Now
Dotmatics 
News

Siemens to Acquire Dotmatics for $5.1B, Strengthening its Position in Life Science Market

Shots:Siemens has entered into an agreement to acquire Dotmatics for $5.1B from Insight Partners, strengthening its position in the life science marketAcquisition will integrate Siemens' manufacturing, industrial simulation, & AI expertise with Dotmatics' complementary offerings, creating an AI-powered product lifecycle management (PLM) portfolio as part of Siemens Xcelerator for seamless R&D-to-manufacturing connectivity Siemens will…
April 3, 2025

Read more

Endo & Mallinckrodt
News

Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock

Shots:Mallinckrodt & Endo to combine their generic pharmaceuticals & Endo’s sterile injectables businesses, later separating the unit, with combined company headquartered in Dublin, Ireland & Endo operating as Mallinckrodt’s subsidiary As per the deal, Endo shareholders will receive $80M in cash & own 49.9% of the combined company, while Mallinckrodt shareholders will hold 50.1%,…
March 18, 2025

Read more

EsoBiotec
News

AstraZeneca to acquire EsoBiotec for ~$1B

Shots:AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing…
March 18, 2025

Read more

News

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M

Shots:Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25 As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in…
March 10, 2025

Read more

Chimerix
News

Jazz Pharmaceuticals to Acquire Chimerix for ~$935M

Shots:Jazz Pharmaceuticals to acquire Chimerix for ~$935M at a price of $8.55 per share in cash. Upon completion in Q2’25, Jazz will acquire remaining shares via second-step merger Acquisition will strengthen Jazz’s rare oncology presence through development & launch of Chimerix’s lead asset, dordaviprone, while adding durable revenue potential with patent protection through…
March 6, 2025

Read more

BBOT
News

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

Shots:BBOT will reverse merge with Helix in a SPAC transaction, where combined entity - "BBOT” will be listed on Nasdaq; closing expected in Q3’25 Upon closing, BBOT will have ~$550M cash (pre-transaction) incl. $100M in existing cash, $196M from Helix’s trust & $260M from PIPE financing. At $10.36/share, the combined entity's implied pro…
March 3, 2025

Read more

BIOTRONIK
News

Teleflex Enters a Definitive Agreement to Acquire BIOTRONIK’s Vascular Intervention Business for ~$797.7M (€760M)

Shots:Teleflex to acquire BIOTRONIK's vascular intervention business for ~$797.7M (€760M) in cash, subject to adjustments. Closing expecting in Q3’25 Acquisition will expand Teleflex’s interventional portfolio with coronary products like Pantera Lux Catheter, PK Papyrus Covered Stent & Orsiro Stent, plus peripheral product like Passeo-18 Lux Catheter, Dynetic-35 Stent, & Pulsar-18 T3 4F Stent,…
February 28, 2025

Read more

Solventum
News

Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B

Shots:Thermo Fisher has entered into definitive agreement with Solventum to acquire its purification & filtration business for ~$4.1B in cash, adding value to its upstream and downstream biologics development & manufacturing Transaction is expected to close by the end of 2025, pending regulatory approval & customary closing conditions Solventum's purification and filtration unit…
February 26, 2025

Read more

bluebird Bio
News

Carlyle & SK Capital to Acquire Bluebird Bio

Shots:Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25 As per the deal, Bluebird stockholders will get $3/share & contingent…
February 24, 2025

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]